Physician profile
Jeevan Sekhar
NPI 1598802852
$467.24
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $81.63 · 2021: $26.52 · 2022: $31.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $95.27 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $53.66 | 2019 | |
| Pfizer INC. | $45.08 | 2019-2022 | |
| Puma Biotechnology, INC. | $28.14 | 2019-2020 | |
| Tersera Therapeutics LLC | $27.00 | 2019 | |
| Merck Sharp & Dohme LLC | $25.85 | 2019 | |
| Incyte Corporation | $22.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.48 | 2019 | |
| Daiichi Sankyo INC. | $18.29 | 2020 | |
| Eisai INC. | $17.77 | 2019 | |
| Genentech USA, INC. | $17.74 | 2019 | |
| Amgen INC. | $17.43 | 2020 | |
| Exelixis INC. | $15.09 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $14.00 | 2019 | |
| Gilead Sciences, INC. | $13.70 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $12.82 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.06 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $10.94 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeevan Sekhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.